Educational Case: From pleural tap to diagnosis: An educational journey in the pathology of mesothelioma Authors: Luke Passannante, Samer N Khader, Laleh Hakima Published: 2026 The following fictional case is intended as a learning tool within the Pathology Competencies for Medical Education (PCME), a set of national standards for teaching pathology. These are divided into three basic competencies: Disease Mechanisms and Processes, Organ System Pathology, and Diagnostic Medicine and Therapeutic Pathology. For additional information, and a full list of learning objectives for all three competencies, see https://doi.org/10.1016/j.acpath.2023.100086.1 Primary objective Objective EM1.5: Occupational Exposure. Provide examples of industrial, occupational, or environmental exposures that produce disease and the resultant pathologic changes in these affected organs from chronic exposure and indicate what organ systems are most commonly affected by which agents. Competency 1: Disease Mechanisms and Processes; Topic EM: Environmental Mechanisms; Learning Goal 1: Injury from External Agents. Secondary objective Objective SP1.2: Differential Diagnosis. List the major differential diagnoses for a surgical pathology specimen obtained from a lesion or mass in a particular location, and describe appropriate further studies to resolve the differential. Competency 3: Diagnostic Medicine and Therapeutic Pathology; Topic SP: Surgical Pathology; Learning Goal 1: Role in Diagnosis. Patient presentation A 67-year-old man presents with new-onset intermittent chest pain. He states that his symptoms gradually started over the past few months and have been worsening. His chest pain is mostly on the right side and seems to be worse with deep breaths, coughing, or sneezing. The pain does not radiate into his arm or extend up into his neck. He has had a cough and dyspnea for the past 4 months, and now gets short of breath with one flight of stairs. In addition, he has lost 15 pounds unintentionally in the past few months and has had excessive fatigue for the past 2 weeks. Past medical history is significant for hypertension, back pain, and generalized anxiety. The patient has a 40-pack-year history of smoking cigarettes and drinks alcohol socially. He does not use illicit drugs. The patient is a retired construction worker and lives with his wife. Diagnostic findings, Part 1 Patient is awake, alert, oriented and in mild distress, appearing somewhat anxious and fatigued. His respiratory rate is slightly increased (18 breaths per minute) with the remaining vital signs within normal limits. The heart has a normal rate and rhythm. On auscultation of the lungs, there is decreased air movement with diminished breath sounds in the right lung and a unilateral dullness to percussion at the right lung base. The abdomen is soft, symmetric, and nontender without distention. There is no pedal edema. There is no lymphadenopathy. Questions/discussion points, Part 1 Based on the clinical presentation, what is the most likely differential diagnosis for this patient? The physical exam findings are concerning for a pleural effusion. The differential diagnosis includes pneumonia, pulmonary embolism, interstitial lung disease, congestive heart failure as well as malignancies, both primary and metastatic. The patient's symptoms appear to be gradually worsening, and he is afebrile; therefore infection (pneumonia) and pulmonary embolism are less likely. Congestive heart failure is also less likely due to the absence of pedal edema. Malignancy remains high on the differential. What initial diagnostic testing is available for this patient? Chest imaging (X-ray and computed tomography [CT]) is generally done as part of the initial symptom evaluation. Routine laboratory tests, including a complete blood count and metabolic panel, erythrocyte sedimentation rate, and lactate dehydrogenase should be considered. The combination of leukocytosis and an elevated ESR (Erythrocyte Sedimentation Rate) may indicate an infectious etiology. An elevated serum lactate dehydrogenase (LDH) may be seen in infectious as well as malignant conditions. Pulmonary function tests should be considered to evaluate residual lung function. Diagnostic findings, Part 2 A large right pleural effusion is noted on the chest X-ray. Thoracentesis is performed, and fluid is sent to cytopathology for evaluation. Contrast-enhanced CT of the chest shows diffuse pleural thickening and pleural plaques. Serum LDH is normal. Cytopathology examination of the pleural fluid shows a cellular fluid with enlarged singly dispersed and clustered cells with scalloped edges, normal to slightly increased nuclear-to-cytoplasmic ratios, round centrally placed nuclei with prominent nucleoli, and a moderate amount of dense cytoplasm. Occasional binucleated cells and mitotic figures are seen (Fig. 1, Fig. 2). The differential diagnosis includes adenocarcinoma and mesothelioma. A cell block is prepared (Fig. 3) and ancillary immunohistochemical studies are performed. Cellular fluid with enlarged, loosely clustered, and singly dispersed cells and occasional mitotic figures (Diff Quik, 20X). Cluster of cells with scalloped edges, increased nuclear-to-cytoplasmic ratios, round central nuclei with prominent nucleoli (arrow), and a moderate amount of dense cytoplasm (Papanicolaou, 40X). Cell block preparation shows single and clustered cells with round nuclei, prominent nucleoli, and moderate cytoplasm (H&E, 20X). H&E: hematoxylin and eosin. Questions/discussion points, Part 2 What ancillary studies are used in the diagnostic work-up of mesothelioma? There are several commonly used immunohistochemical stains for the diagnosis work-up of mesothelioma. These immunohistochemical stains aid pathologists in differentiating mesothelioma from benign mesothelial proliferations as well as from other more common types of malignancies, such as primary lung adenocarcinoma or metastasis from a different site. Markers specific for mesothelial cells include Calretinin and D2-40. These stains will be positive in benign and neoplastic mesothelial cells and negative in primary lung or metastatic adenocarcinomas. BAP1 (BRCA1-asociated protein 1) is a marker normally expressed in benign cells, and loss of BAP1 stain is helpful in differentiating between benign versus malignant mesothelial proliferations. BAP1 staining will be intact in adenocarcinomas. Markers negative in mesothelial cells and positive in adenocarcinoma include MOC31 and BEREP4; TTF1 and NapsinA will be positive specifically in primary lung adenocarcinomas. What are the advantages and limitations of cytopathologic evaluation of fluids? Exfoliative cytopathology refers to the evaluation of cells suspended in the pleural fluid. The advantages generally include less invasive and less expensive procedures to acquire samples and a quick turnaround-time. The limitations include lower sensitivity due to variable sample cellularity, lack of tissue architecture, and inability to evaluate for the presence of invasion (one of the key diagnostic features of malignant mesothelioma). What method should be used to obtain a definitive diagnosis? Bronchoscopy with endobronchial ultrasound (EBUS)-guided biopsy allows for excellent visualization of the respiratory bronchi, removal of secretions/foreign bodies, and biopsy of any abnormalities including lung lesions or enlarged mediastinal lymph nodes. In this case, no endobronchial lesions were seen. In view of the CT findings of diffuse pleural thickening and plaques, fine needle aspiration biopsy, video-assisted thoracoscopic (VATS) biopsy, or open thoracotomy can be performed to biopsy the pleural plaques. Diagnostic findings, Part 3 Immunohistochemical stains for calretinin and D2-40 are strongly positive, consistent with mesothelial origin; BAP-1 shows loss of nuclear staining (Fig. 4, Fig. 5). The findings are supportive of the diagnosis of mesothelioma. (A) Calretinin stain is positive, supporting the mesothelial origin of the cells (20X); (B) D240 stain is positive, supporting the mesothelial origin of cells (20X). BAP-1 stain shows loss of nuclear staining in mesothelial clusters (20X), while the background lymphocytes retain staining and serve as an internal positive control. Video-assisted thoracoscopic (VATS) biopsy shows a single-layer surface proliferation of neoplastic mesothelial cells with atypia, consistent with at least mesothelioma in-situ (Fig. 6). Core biopsy of pleural plaques shows surface proliferation of neoplastic mesothelial cells with prominent nucleoli (H&E, 40X). Questions/discussion points, Part 3 What are mesothelial cells? What pathologic processes affect mesothelial cells? Mesothelial cells line the serous surfaces of the pleural, pericardial and peritoneal cavities. The pleura is a continuous membrane that covers the lung (visceral pleura) and the chest wall (parietal pleura). Mesothelial cells appear as a single layer of cuboidal epithelium, 16–40 μm in diameter, anchored to a basement membrane. They are rarely seen in histologic sections but may exfoliate and be visualized in cytologic preparations of pleural fluids (or peritoneal washings). Mesothelial cells display round central nuclei, a moderate amount of cytoplasm, and well-defined fuzzy cell borders or “skirts,” due to the presence of numerous microvilli. Mesothelial cells can undergo proliferative or hyperplastic changes in response to a variety of conditions, such as injury, inflammation, or infection. Reactive mesothelial cells appear larger with open chromatin and prominent nucleoli. When clustered, reactive mesothelial cells form a scalloped (knobby) outside border. A few mitotic figures may be seen. Large, complex clusters and papillary projections are not usually seen in benign proliferations. Intercellular spaces or “windows” are small spaces that can be seen between adjacent mesothelial cells and are a feature of reactive mesothelial cell populations and help distinguish them from adenocarcinoma. Mesothelioma is an insidious neoplasm arising from the mesothelial surfaces, the majority of which are pleural in origin. The annual incidence of mesothelioma in the United States is estimated to be approximately 3300 cases per year.2 This incidence has been gradually declining due to increased awareness of risk factors associated with the development of mesothelioma and the ensuing regulations in the workplace environment.3 Mesothelioma is most prevalent in adults >60 years of age and has a marked male predilection (M:F = 9:1).4 What are the risk factors and underlying pathogenesis of mesothelioma? Occupational exposure to asbestos is the most important risk factor associated with the development of pleural mesothelioma. Asbestos, due to its sturdy and heat-resistant properties, has been mined and used in the building and shipyard industry (cement, roofs, tiles, and insulation), friction products (automobile brakes and transmission parts), fabrics, and paint coatings, among others. Different asbestos fiber types are associated with varying degrees of carcinogenicity. Amphiboles (found in rocks) are the most potent while crocidolite is more dangerous.4 Inhalation or ingestion of asbestos fibers leads to embedding of these small fibers in the mesothelium which triggers an inflammatory response and leads to tissue scarring or “pleural plaques”. In some cases, DNA damage leads to uncontrolled cancerous growth and the development of mesothelioma. Not all patients with pleural plaques develop mesothelioma, and some patients with mesothelioma may not have visible pleural plaques. The lifetime risk of developing mesothelioma among asbestos workers is thought to be as high as 10%.5 There appears to be a dose-response association between asbestos exposure and mesothelioma. There is also a long latency period between disease development and exposure (30–40 years).6 The incidence of mesothelioma is markedly increased when risk factors are combined with cigarette smoking. Smoking damages lung tissue and impairs clearance of irritants, such as asbestos fibers, which leads to inflammation, potentially accelerating mesothelioma development. Other etiologies associated with the development of mesothelioma include Simian virus (SV40) and ionizing radiation.4 It is important to note that despite a stronger association with asbestos exposure, mesothelioma is still far less common than lung adenocarcinoma in patients with asbestos exposure. How is mesothelioma classified histologically? Malignant mesothelioma is divided into diffuse (the majority) and localized types. The diffuse growth pattern may consist of multiple small nodules, plaque-like masses, or confluent rind-like sheets. The World Health Organization (WHO) classification divides diffuse malignant mesothelioma into epithelioid, sarcomatoid (including desmoplastic), and biphasic (contain both epithelioid and sarcomatoid subtypes, each representing at least 10% of the tumor) subtypes.7,8 Localized mesotheliomas are sharply circumscribed, and although rare, are important to recognize since they are potentially treatable by complete resection and carry a better diagnosis.8 The epithelioid variant will shed cells into pleural fluids as seen in this case. What are the diagnostic criteria for mesothelioma in-situ? Mesothelioma in-situ is a preinvasive single-layer surface proliferation of neoplastic mesothelial cells, with or without atypia. The diagnostic criteria include (a) recurrent pleural effusion, (b) no thoracoscopic or imaging evidence of tumor, and (c) loss of BAP1 and/or MTAP by immunohistochemistry and/or CDKN2A homozygous deletion by fluorescence in-situ hybridization.9 Diagnostic findings, Part 4 Pleural decortication shows diffuse, epithelioid type, malignant mesothelioma with invasion into the underlying stroma (Fig. 7). Malignant mesothelioma, epithelioid type, with invasion into the underlying stroma (H&E, 10X). H&E: hematoxylin and eosin. Questions/discussion points, Part 4 What ancillary molecular tests are available for diagnosis of mesothelioma? Fluorescence in situ hybridization (FISH) is a technique that uses DNA marked with fluorescent probes to identify microdeletions, translocations, duplications of genes or other chromosomal abnormalities. The detection of homozygous deletion of CDKN2A by FISH can be used in combination with histologic and immunohistochemical evaluation to confirm the diagnosis of malignant mesothelioma (Fig. 8). However, a homozygous deletion is not present in all mesotheliomas or may not be detected if it is below the assay threshold, so a negative result does not exclude the diagnosis of malignant mesothelioma. Fluorescence in situ hybridization for the CDKN2A gene in malignant mesothelioma using the LSI CDKN2A (9p21)/CEP9 Dual Color Probe. Homozygous loss, designated by the absence of red signals in the nuclei, was identified in 37.5% of the cells analyzed in this case. A common cutoff for homozygous deletion is typically around 20%–30% of nuclei showing loss of both CDKN2A signals in tumor cells. How is pathologic staging of mesothelioma determined? Pathologic staging is usually performed after attempted surgical resection of the primary tumor. Pathologic staging depends on pathologic documentation of the anatomic extent of disease (involvement of ipsilateral pleural surfaces, diaphragmatic muscle, underlying pulmonary parenchyma, endothoracic fascia, mediastinal fat, chest wall extension, rib destruction, and extension into spine) and whether the primary tumor has been completely removed. What are the treatment options for mesothelioma? Treatment includes surgical approaches for localized disease, such as pleural decortication and extrapleural pneumonectomy. Pleural decortication is a simple procedure that involves excision of the thick fibrinous peel or rind from the pleural surface. Adjuvant therapy, including chemotherapy and immunotherapy, is used in locally advanced or unresectable disease.10,11 Palliative radiation is used for advanced cases.4 What is the prognosis of mesothelioma? Malignant mesothelioma is associated with a poor overall survival (average: 12–18 months).4 Pure epithelioid mesothelioma is associated with a slightly better outcome compared with sarcomatoid and biphasic mesotheliomas. The International Association for the Study of Lung Cancer (IASLC) database examines outcomes in surgically managed patients with malignant pleural mesothelioma. Significant differences in overall patient survival have been reported among those treated with curative versus palliative-intent surgery (median survival 18 versus 12 months, P < 0.0001). The type of curative-intent procedure (extrapleural pneumonectomy [EPP] vs. pleurectomy/decortication [P/D]) is also associated with a significant impact on survival in lower stage disease (median survival of 40 months for EPP vs. 23 months for P/D). No differences in survival have been reported between procedure types in higher stage disease.12 Teaching points •Mesothelioma is associated with chronic exposure to asbestos and high-risk industries such as construction, including demolishing old buildings, shipbuilding, and factory work. Mesothelioma is associated with chronic exposure to asbestos and high-risk industries such as construction, including demolishing old buildings, shipbuilding, and factory work. •The clinical presentation of mesothelioma typically involves a long asymptomatic period followed by nonspecific pulmonary symptoms. These symptoms include shortness of breath, pleuritic chest pain, cough, and weight loss. The onset of these symptoms follows an insidious course. The clinical presentation of mesothelioma typically involves a long asymptomatic period followed by nonspecific pulmonary symptoms. These symptoms include shortness of breath, pleuritic chest pain, cough, and weight loss. The onset of these symptoms follows an insidious course. •The diagnostic work-up for pleural mesothelioma involves assessing the lungs on physical exam to determine if the patient has a pleural effusion, which would present with decreased breath sounds and/or dullness to percussion. Imaging studies include chest X-ray and chest CT, the latter of which can better reveal pleural masses, plaques, calcifications, or effusions. The diagnostic work-up for pleural mesothelioma involves assessing the lungs on physical exam to determine if the patient has a pleural effusion, which would present with decreased breath sounds and/or dullness to percussion. Imaging studies include chest X-ray and chest CT, the latter of which can better reveal pleural masses, plaques, calcifications, or effusions. •Pleural fluid analysis and/or fine-needle aspiration biopsy of pleural plaques allows for cytomorphology and immunohistochemical staining evaluation. Video-assisted thoracoscopic biopsy allows for more comprehensive ancillary work-up including molecular studies. Pleural fluid analysis and/or fine-needle aspiration biopsy of pleural plaques allows for cytomorphology and immunohistochemical staining evaluation. Video-assisted thoracoscopic biopsy allows for more comprehensive ancillary work-up including molecular studies. •Mesotheliomas are rare and, the differential diagnosis includes metastatic primary lung adenocarcinoma to the pleura, which is more common. Pleural fluid cytology and pleural biopsy examinations are used to exclude metastatic tumors and distinguish between benign mesothelial proliferations and malignant mesothelioma. Mesotheliomas are rare and, the differential diagnosis includes metastatic primary lung adenocarcinoma to the pleura, which is more common. Pleural fluid cytology and pleural biopsy examinations are used to exclude metastatic tumors and distinguish between benign mesothelial proliferations and malignant mesothelioma. •Mesothelioma is a malignant neoplasm of the mesothelium, which is a thin layer of cuboidal cells of mesodermal origin lining the serosal cavities. Pleural mesothelioma is most common and affects the pleura surrounding the lungs. Mesotheliomas can less frequently involve the pericardium or peritoneum. Mesothelioma is a malignant neoplasm of the mesothelium, which is a thin layer of cuboidal cells of mesodermal origin lining the serosal cavities. Pleural mesothelioma is most common and affects the pleura surrounding the lungs. Mesotheliomas can less frequently involve the pericardium or peritoneum. •There are three histological subtypes of mesotheliomas. Mesothelioma can be epithelioid, sarcomatoid, or mixed. There are three histological subtypes of mesotheliomas. Mesothelioma can be epithelioid, sarcomatoid, or mixed. •Treatment can include surgery, chemotherapy, immunotherapy, and palliative radiation, depending on tumor stage and histological type. Treatment can include surgery, chemotherapy, immunotherapy, and palliative radiation, depending on tumor stage and histological type. •Malignant mesothelioma is associated with a poor overall survival (average: 12–18 months). Patients treated with curative-intent procedures have better overall survival. Malignant mesothelioma is associated with a poor overall survival (average: 12–18 months). Patients treated with curative-intent procedures have better overall survival. Funding The article processing fee for this article was funded by an Open Access Award given by the Society of ‘67, which supports the mission of the Association for Academic Pathology to produce the next generation of outstanding investigators and educational scholars in the field of pathology. This award helps to promote the publication of high-quality original scholarship in Academic Pathology by authors at an early stage of academic development. Declaration of competing interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper. Acknowledgement We would like to acknowledge Dale W Lewis, from the Department of Pathology and Laboratory Medicine at the University of Pittsburgh Medical Center, for providing Fig. 8 included in this paper. References